Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
IPO Year: 2021
Exchange: NASDAQ
Website: sophiagenetics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/18/2024 | $11.00 | Buy | Craig Hallum |
8/7/2024 | $10.00 → $5.00 | Overweight → Equal-Weight | Morgan Stanley |
6/27/2024 | $6.00 | Buy | Guggenheim |
11/29/2023 | $8.00 | Outperform | RBC Capital Mkts |
7/5/2023 | $10.00 | Overweight | JP Morgan |
1/3/2023 | $6.00 | Buy | BTIG Research |
11/23/2022 | $2.00 | Neutral | Credit Suisse |
2/15/2022 | $23.00 → $18.00 | Overweight | Morgan Stanley |
10/15/2021 | Outperform | Cowen | |
8/17/2021 | $24.00 | Overweight | Morgan Stanley |
144 - SOPHiA GENETICS SA (0001840706) (Subject)
6-K - SOPHiA GENETICS SA (0001840706) (Filer)
144 - SOPHiA GENETICS SA (0001840706) (Subject)
6-K - SOPHiA GENETICS SA (0001840706) (Filer)
6-K - SOPHiA GENETICS SA (0001840706) (Filer)
6-K - SOPHiA GENETICS SA (0001840706) (Filer)
144 - SOPHiA GENETICS SA (0001840706) (Subject)
20-F - SOPHiA GENETICS SA (0001840706) (Filer)
6-K - SOPHiA GENETICS SA (0001840706) (Filer)
144 - SOPHiA GENETICS SA (0001840706) (Subject)